Therefore, these findings indicated that MGCD, an HDAC inhibitor, attenuates aortic remodeling in rats with TAC-induced pressure overload rats and may serve as a potential therapeutic target of anti-aortic remodeling in pressure overload-induced hypertension-related diseases. Here, HDAC9 is linked to Hypertension.